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Unstructured abstract 
Research evidence guiding the identification of pragmatic and effective actions aimed at 
improving the selection, availability, affordability and rational prescribing of medicines for 
mental disorders is sparse and inconsistent. In order to boost the development of new research, 
in this commentary we suggest to organise and classify all the activities in this area under a 
common theoretical framework and nomenclature, adopting ƚŚĞ ƚĞƌŵ  ?ƉƵďůŝĐ ŚĞĂůƚŚ
ƉƐǇĐŚŽƉŚĂƌŵĂĐŽůŽŐǇ ? ?WƵďůŝĐŚĞĂůƚŚƉƐǇĐŚŽƉŚĂƌŵĂĐŽůŽŐǇŝƐproposed as a research discipline, 
based on contributions from the fields of regulatory science, health services research and 
implementation science. Implementing the term public health psychopharmacology may offer 
advantages, as the scientific community would be more focused on common goals and 
objectives, with, likely, an increasing body of research evidence of practical use.  
 
Key-words: selection of medicines, availability, affordability, rational prescribing, psychotropic 
medicines  
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Main Manuscript 
Appropriate use of medicines for mental disorders is a major challenge worldwide, being based 
on a complex interaction of different aspects, such as a functioning selection process, a dynamic 
health infrastructure assuring medicine availability and affordability, and an effective set of 
policies enhancing rational prescribing (Barbui et al., 2017a). Appropriate use of medicines has 
been conceptualized as the expectation that individuals receive medicines that are appropriate 
to their clinical needs, in doses that meet their individual requirements, for an adequate period 
of time, and at the lowest cost to them and their community (World Health Organization, 
2015a).  
In order to improve access and appropriate use of medicines for mental disorders, the 
Gulbenkian Mental Health Platform and the WHO Department of Mental Health and Substance 
Abuse recently worked on the identification of a set of practical key actions to be implemented 
by policy makers and clinicians in charge of governing mental health systems (Barbui et al., 
2016). One aspect that the document clearly highlighted is the paucity and sparseness of 
research evidence to guide the identification of pragmatic and effective actions. As a 
consequence, most actions were recommended more on the basis of common sense and 
exemplary practice than on research findings.  
Lack of an adequate evidence base needs to be properly addressed. One way to give more 
visibility to the existing research activities in this area, and to boost the development of new 
multidisciplinary projects and innovation initiatives, is to organise and classify all the research 
efforts aimed at increasing knowledge on aspects related to access, rational prescribing, and 
appropriate use of medicines for mental disorders, under a common theoretical framework and 
nomenclature. Here we suggest ƚŚĞƚĞƌŵ ?ƉƵďůŝĐŚĞĂůƚŚƉƐǇĐŚŽƉŚĂƌŵĂĐŽůŽŐǇ ? ?W,W ? ? 
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PHP should be considered a research discipline. Regulatory science, health services research and 
implementation science may represent research areas of interest (Figure 1). For each of these 
research areas, challenges, aims and examples of research activities relevant to PHP may be 
identified (Table 1). 
Insert Figure 1 
Insert Table 1 
A first challenge for PHP is to increase knowledge on how psychotropic medicines should be 
effectively selected. Research evidence is needed to help countries, regions, health districts and 
non-governmental organizations develop and implement effective rules governing the approval 
of psychotropic medicines. Examples of research areas that PHP should cover include: 
x analyses of the consequences of accepting the use of placebo in conditions where active 
psychotropic medicines are available (Barbui and Bighelli, 2013a; Ostuzzi et al., 2017), 
as well as ensuring appropriate doses of comparators, which was a concern with the 
second generation antipsychotics (Geddes et al., 2000);  
x the role of superiority versus non-inferiority versus equivalence designs (Barbui and 
Bighelli, 2013b; Garattini and Bertele', 2007);  
x the potential added value of regulatory meta-analyses as an integral part of the drug 
approval process (Barbui et al., 2017b), ideally associated with a thorough qualitative 
appraisal of data (e.g. by employing the GRADE approach). The inclusion of systematic 
descriptions of the evidence in support or against a new psychotropic medicine in public 
assessment reports not only would ensure transparency, but could also orientate future 
research in effectively addressing evidence-to-practice gaps (Barbui et al., 2017b). 
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These regulatory themes are within the scope of PHP and should require careful research 
consideration (Garattini and Chalmers, 2009). 
A second challenge for PHP is to increase knowledge on strategies to make psychotropic 
medicines available across mental health systems at affordable prices, especially in lower and 
middle income countries where an appreciable proportion of medical costs are out-of-pocket 
and illness can have catastrophic consequences on the family (World Health Organization, 
2015b). Research evidence is needed to help countries, regions, health districts and non-
governmental organizations develop and implement effective and sustainable policy actions 
(World Health Organization, 2003). Examples of research areas that PHP should cover include 
analyses of factors related to the development of sustainable and reliable medicine supply 
systems, studies on the impact of different regulation systems for psychotropic medicines 
recognizing that boundaries between certain classes such as first and second generation anti-
psychotic medicines are becoming blurred, studies investigating measures to limit the diffusion 
of counterfeit or substandard or degraded psychotropic medicines, and analyses of different 
financing systems to ensure economic sustainability at affordable prices for the end-user. This 
includes making quality generic medicines available at low prices (Woerkom et al., 2012) , with 
typically no difference in outcomes between generics and originators to reduce co-payments as 
an issue. Furthermore, the area of health services research may be interested in evaluating 
particular needs of selected settings (for example prisons, emergency or humanitarian settings), 
where prescriptions may be particularly high in number, used off-label with poor clinical 
rationale, or not supported by adequate clinical resources (e.g. laboratory tests for monitoring 
adverse events) (Hassan et al., 2016). This would provide an evidence base for rationally 
addressing prescribing attitudes in settings where common guidelines do not easily apply. These 
health services themes are within the scope of PHP and should require careful research 
consideration. 
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Selected psychotropic medicines that are available at affordable prices should be rationally 
prescribed and appropriately used ĂĐĐŽƌĚŝŶŐƚŽƚŚĞĐŽŶƚĞǆƚ ?ƐĨĞĂƚƵƌĞƐ. Examples of irrational 
use of psychotropic medicines include prescribing or dispensing too many medicines per patient 
(polypharmacy), prescribing inappropriate dosages, poor adherence to correctly prescribed 
medications, as well as misuse, underuse or overuse (Jaracz et al., 2014). At a global level, more 
than 50% of all medicines are prescribed, dispensed or sold inappropriately, and half of all 
patients fail to take them correctly (Osterberg and Blaschke, 2005). Therefore, a third challenge 
for PHP is to produce knowledge that may support rational prescribing and appropriate use of 
medicines building on initiatives such as the Essential Medicines List (World Health Organization, 
2015a). A number of research activities and study designs, with the background rationale of 
filling the gap between the production of evidence and its uptake in practice, may be employed 
(Table 1) including systematic reviews of randomised or observational evidence, evidence-based 
guidelines, pharmacoepidemiological studies based on administrative databases, observational 
or randomised studies with pragmatic designs. PHP should effectively implement these research 
tools to discover better and more effective strategies to support physicians in optimizing the use 
of psychotropic medicines. We argue that more than the development of new and more 
effective psychotropic medicines, the greatest benefit in the next decade will derive from the 
generation of knowledge on how to provide better care based on current treatments. 
Organising research activities on aspects related to access, rational prescribing and appropriate 
use of medicines for mental disorders under a common nomenclature may offer advantages. 
The scientific community would be more focused on common goals and objectives, with, likely, 
an increasing body of research evidence of practical use. International calls for funding may be 
interested in supporting research in the area of PHP, and scientific societies and journals might 
be more open to recognise the value of research in this area. Junior scientists and clinicians may 
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appreciate that research activities in this area, being focused on implementation and quality of 
care, may effectively complement clinical practice.  
Ultimately, the search for a better understanding of how psychotropic medicines should be 
effectively selected, made available to those in need at affordable prices, and prescribed 
rationally, is of importance to improving mental health care of individuals with these disorders 
in all countries. This is the ultimate goal of PHP.  
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Table 1. Description of the main aims and research activities of public health 
psychopharmacology 
 
RESEARCH 
AREA 
 
CHALLENGE GENERAL AIM EXAMPLES OF RESEARCH 
ACTIVITIES 
 
Regulatory 
science 
Selection of 
psychotropic 
medicines 
Improving the 
rules governing 
the approval 
process of 
psychotropic 
medicines  
Analyses of the beneficial and 
harmful consequences of using 
placebo in conditions where active 
psychotropic medicines are 
available 
Analyses of superiority versus non-
inferiority versus equivalence 
designs 
Analyses of the potential role of 
regulatory meta-analyses in the 
approval process for psychotropic 
medicines 
Analyses of the consequences of 
using a systematic description of 
the evidence in support or against 
a new psychotropic medicine in 
public assessment reports 
Health services 
research 
Availability and 
affordability of 
psychotropic 
medicines 
Improving timely 
obtainability of 
psychotropic 
medicines in the 
mental health 
system at 
affordable prices 
Analyses of factors related to the 
development of sustainable and 
reliable supply systems 
Development of studies on the 
beneficial and harmful 
consequences of different 
regulation systems for 
psychotropic medicines 
Epidemiological studies on factors 
associated with counterfeit or 
substandard or degraded 
psychotropic medicines 
Analyses of health system factors 
related to distribution strategies to 
reach those in need 
Analyses of different financing 
systems to ensure economic 
sustainability for the health system 
Epidemiological analyses of 
different policies for affordable 
prices for the end-user 
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Implementation 
science 
Appropriate 
use of 
psychotropic 
medicines 
Improving 
rational 
prescribing and 
appropriate use 
of psychotropic 
medicines 
Production of systematic reviews 
of randomized and observational 
studies 
Development of evidence-based 
guidelines and recommendations 
Analyses of administrative 
information systems to monitor 
trends in psychotropic medicine 
prescribing and to establish 
associations between medicine 
exposure and outcome variables  
Development of training and 
education activities, including audit 
and feedback initiatives 
Development of epidemiological 
and pragmatic intervention studies 
on the beneficial and harmful 
consequences of psychotropic 
medicines 
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Figure 1. Research areas of interest for public health psychopharmacology 
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